Key takeaways
Verkazia (cyclosporine) and Restasis (cyclosporine) are both immunosuppressant medications used to treat eye conditions, but they have different FDA-approved uses. Verkazia is specifically approved for vernal keratoconjunctivitis (VKC), a rare allergic eye condition, while Restasis is approved for treating dry eye in people aged 16 and older. Both medications are calcineurin inhibitors that help reduce inflammation in the eyes. Verkazia is used as an eye drop four times a day, whereas Restasis is used twice a day. Verkazia is available only as a brand-name medication, while Restasis has a lower-cost generic option available for its single-use vials. Common side effects of Verkazia include temporary eye pain and itchiness, while Restasis often causes a burning sensation in the eye. Both medications should not be used with contact lenses, and you should wait at least 15 minutes before reinserting them after application.
